Nicolas Sabarth | Research Laboratory Head in Biotherapeutics Discovery and Cancer Immunology
Boehringer-Ingelheim

Nicolas Sabarth, Research Laboratory Head in Biotherapeutics Discovery and Cancer Immunology, Boehringer-Ingelheim

Nicolas Sabarth is heading a biotherapeutics discovery group at Boehringer-Ingelheim Vienna, Austria. He received his PhD from the Max-Planck-Institute for Infection Biology, Germany.  Since then, he held positions of increasing responsibility in the R&D departments of GlaxoSmithKline, Intercell, and Baxalta. He is a drug discovery professional with emphasis on innovate biotherapeutics in immuno-oncology, immunology and oncology. His expertise is therapeutic concept validation, antibody discovery, and antibody engineering. In particular, multispecific antibody concepts and T cell engagers are at the center of his research

Appearances:



Festival of Biologics Day 2 @ 15:20

Advances in pHLA directed T cell engager discovery and design

  • HLA/peptide complex directed T cell engager enabling targeting of tumor associated intracellular proteins by biotherapeutics
  • Potency and specificity are key attributes for the design of TCR mimic T cell engager
  • Here, display technologies, pHLA-Fv structures, focused library design, and innovative bispecific formats were combined to optimize pharmacology enabling and specific T cell engager
last published: 01/Jul/22 16:05 GMT

back to speakers